Patents by Inventor Daniel J. Canney

Daniel J. Canney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 10676464
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: June 9, 2020
    Assignee: Temple University Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL MODULATORS OF THE SIGMA-2 RECEPTOR AND THEIR METHOD OF USE
    Publication number: 20200039985
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: March 15, 2018
    Publication date: February 6, 2020
    Inventors: Benjamin E. Blass, Daniel J. Canney, Kevin M. Blattner
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 10544117
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives of formula (I) having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: January 28, 2020
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE
    Publication number: 20190367528
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: November 15, 2017
    Publication date: December 5, 2019
    Inventors: Daniel J. Canney, Benjamin E. Blass, Kevin M. Blattner, Douglas A. Pippin
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20190367493
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: May 14, 2019
    Publication date: December 5, 2019
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 10287274
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: May 14, 2019
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 10239868
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: March 26, 2019
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE
    Publication number: 20180221365
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
    Type: Application
    Filed: May 11, 2016
    Publication date: August 9, 2018
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Kevin Blattner
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20180016261
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20180016262
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • 5-hydroxytryptamine receptor 7 activity modulators and their method of use
    Patent number: 9802924
    Abstract: Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 31, 2017
    Assignee: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Novel 5-Hydroxytryptamine Receptor 7 Activity Modulators and Their Method of Use
    Publication number: 20170298037
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: September 10, 2015
    Publication date: October 19, 2017
    Applicant: Temple University-Of the Commonwealth System of Higher Education
    Inventors: Daniel J. Canney, Benjamin E. Blass, Rong Gao, Magid Abou-Gharbia
  • Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2B activity modulators
    Patent number: 9464062
    Abstract: Pharmaceutical compositions of the invention comprise disubstituted oxazolidin-2-ones derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 2b activity.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 11, 2016
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. Canney, Richie R. Bhandare, Benjamin E. Blass, Magid Abou-Gharbia
  • NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
    Publication number: 20160016941
    Abstract: Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicant: TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Daniel J. CANNEY, Benjamin E. BLASS, Rong GAO, Magid ABOU-GHARBIA
  • DISUBSTITUTED OXAZOLIDIN-2-ONES 5-HYDROXYTRYPTAMINE RECEPTOR 2B ACTIVITY MODULATORS
    Publication number: 20150291539
    Abstract: Pharmaceutical compositions of the invention comprise disubstituted oxazolidin-2-ones derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 2b activity.
    Type: Application
    Filed: November 26, 2013
    Publication date: October 15, 2015
    Inventors: Daniel J. Canney, Richie R. Bhandare, Benjamin E. Blass, Magid Abou-Gharbia